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Erlotinib for Whole-
Brain-Radiotherapy-
Refractory 
Leptomeningeal 
Metastases After 
Gefitinib Failure in a 
Lung Adenocarcinoma 
Patient
To the Editor:
We read with interest the recent 
article by Morris et al.1 on the nega-
tive impact of whole brain radiotherapy 
(WBRT) for leptomeningeal metastases 
(LM). WBRT is commonly performed 
as the first choice for diffuse-type brain 
metastases. However, WBRT is occa-
sionally ineffective, especially in cases 
combined with LM. We experienced a 
case with an epidermal growth factor 
receptor (EGFR)-sensitive mutation in 
which WBRT-refractory central nervous 
system (CNS) metastases markedly 
responded to erlotinib after gefitinib 
failure, and herein present the case.
A 66-year-old woman was 
referred to our institution, diagnosed 
with metastatic adenocarcinoma of the 
lung. Initially, a chest computed tomog-
raphy showed multiple pulmonary 
metastases and pleural and pericardial 
effusions. Drainage of the pleural and 
pericardial effusions was performed, 
and cytological examination of the 
pericardial effusion revealed adenocar-
cinoma cells. A point mutation in exon 
21 (L858R) was detected in the EGFR 
mutational analysis. Her performance 
status (Eastern Cooperative oncology 
Group) was 2, and we administered 
gefitinib as the first-line therapy. 
Remarkable response was confirmed, 
and the effusions mostly disappeared. 
Although the response continued for 
18 months, she complained of gait 
disturbance during gefitinib therapy. 
Brain magnetic resonance imaging 
(MRI) showed multiple brain metasta-
ses (Figure 1A). We withdrew gefitinib 
and administered WBRT. After WBRT, 
her symptoms and MRI findings fur-
ther deteriorated (Figure 1B). We sus-
pected that these brain metastases were 
complicated by LM. Cerebrospinal 
fluid (CSF) cytology did not reveal 
malignant cells, but an L858R muta-
tion (without T790M) was detected by 
EGFR mutational analysis. We then 
initiated erlotinib as the second-line 
therapy. A month after erlotinib initia-
tion, neurological symptoms and brain 
MRI findings dramatically improved 
(Figure 1C). Two months later, she was 
transferred to another hospital near her 
home.
A high frequency of CNS relapse 
has been suggested in EGFR-tyrosine 
kinase inhibitor (TKI) treatment periods.2 
Treatments for CNS relapse are therefore 
important after EGFR-TKI failure.
Although WBRT is frequently 
performed for diffuse types of brain 
metastases, even during EGFR-TKI 
therapy, WBRT is not always effective. 
If WBRT is not effective for diffuse 
types of brain metastases, we should 
assume these metastases are compli-
cated by LM. We suspected LM after 
WBRT failure, and LM was definitively 
diagnosed via the detection of an EGFR 
mutation in the CSF, despite the absence 
of cytological confirmation. Shingyoji 
et al.3 have demonstrated EGFR muta-
tional analysis is useful in diagnosing 
LM. In their study, EGFR mutations 
were detected in five (31%) of 16 
patients with negative CSF cytology. 
A highly sensitive polymerase chain 
reaction technique can detect DNA 
fragments in the CSF despite negative 
CSF cytology.
Several reports have demonstrated 
erlotinib efficacy after gefitinib failure 
for CNS metastases, especially in com-
bination with LM.4 Low penetration of 
gefitinib into the CNS is considered to 
be the cause of CNS resistance to gefi-
tinib.5 However, erlotinib has a higher 
concentration in the CNS, and thus was 
extremely effective for LM after gefi-
tinib failure, as demonstrated in our 
present case.
our present case showed a 
lack of WBRT effectiveness for LM. 
Furthermore, Morris et al. have demon-
strated that survival was not improved 
by WBRT for LM. They also sug-
gested the importance of EGFR-TKIs 
for patients with LM harboring EGFR 
mutations. In such patients, EGFR-
TKIs should be administered before 
WBRT. Additionally, erlotinib should 
be administered before WBRT, espe-
cially in such patients after gefitinib 
failure. Further studies are warranted 
to confirm our observation.
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Epidermal Growth 
Factor Receptor 
Mutation and 
Chemosensitivity
To the Editor:
We read with interest the recent 
article by Yoshimasu et al.1 which con-
cluded that lung cancers with epider-
mal growth factor receptor (EGFR) 
mutations were less sensitive to cis-
platin and docetaxel than those with 
wild-type EGFR based on histoculture 
drug response assays. As this is still a 
controversial issue,2,3 we would like to 
refer you to the results of our recent 
study in which we analyzed a panel of 
non-small cell lung carcinoma cell lines 
for genetic mutations; gene expression 
patterns; and sensitivities to cisplatin, 
paclitaxel, and gefitinib.4
We used a conventional cell 
growth inhibition assay in a 96-well for-
mat, and the results are shown in Figure 
1. our data showed that of the 40 non-
small cell lung cancer cell lines tested, 
EGFR mutants (n = 6) were relatively 
resistant to cisplatin. The IC50 of EGFR 
mutants ranged from 2.5 to 9.5 M. 
Two EGFR mutants, H1650 and H1975, 
showed IC50 values of 2.5 and 4.0 M, 
respectively, and four EGFR mutants 
(HCC827, HCC4006, PC3, and PC14) 
showed IC50 values for cisplatin more 
than 5 M. In our assay, paclitaxel was 
effective for most of the cell lines with 
IC50 values less than 0.1 M. However, 
there were four exceptional cell lines 
that were highly resistant to paclitaxel 
with IC50 values more than 10 M. of 
these four cell lines, two cell lines, PC3 
and PC14, harbored EGFR mutations 
and the other two, Calu3 and H1781, 
FIGURE 1. (A) Brain magnetic resonance image (MRI) before whole brain radiotherapy (WBRT); (B) Brain MRI 1 month after 
WBRT; (C) Brain MRI 1 month after the initiation of erlotinib.
Disclosure: The authors declare no conflicts of 
interest.
Address for correspondence: Toshiro Niki, PhD, MD, 
Department of Pathology, Jichi Medical University, 
3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498 
Japan. E-mail: tniki@jichi.ac.jp
Copyright © 2012 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/12/0704-0771
FIGURE 1. The IC50 values of the 40 non-small cell lung cancer cell lines for cispla-
tin according to the driver mutations and E-cadherin mRNA levels. Cell lines with 
low E-cadherin mRNA are shown in blue and cell lines with high E-cadherin mRNA 
are shown in red. Note that cell lines mutated for EGFR, HER2, MET, and BRAF 
express high levels of E-cadherin mRNA and are mostly resistant to cisplatin. KRAS 
mutants showed distinct sensitivities to cisplatin according to E-cadherin mRNA 
levels. Modified from Matsubara et al.4
